Phathom Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on June 3, 2025. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation matters.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
- Proposal 1 (Election of Class III Directors): Stockholders elected Heidi Kunz and James Topper, M.D., Ph.D. for three-year terms.
- Heidi Kunz: 34,023,182 votes For; 451,384 votes Withheld.
- James Topper: 26,884,171 votes For; 7,590,395 votes Withheld.
- Broker Non-Votes: 17,427,382 for both candidates.
- Proposal 2 (Ratification of Auditor): Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2025.
- Votes For: 51,670,346
- Votes Against: 177,785
- Abstentions: 53,817
- Proposal 3 (Say-on-Pay): Stockholders approved the compensation of named executive officers on a non-binding advisory basis.
- Votes For: 24,584,781
- Votes Against: 8,704,739
- Abstentions: 1,185,046
- Broker Non-Votes: 17,427,382
- Proposal 4 (Say-on-Frequency): Stockholders approved holding future advisory votes on executive compensation annually.
- 1 Year: 30,665,967 votes
- 2 Years: 21,543 votes
- 3 Years: 2,611,188 votes
- Abstentions: 1,175,868
Guidance, Outlook, and Risks
The filing states the Company's intent to hold future advisory stockholder votes on executive compensation annually, consistent with the Board's recommendation and the Say-on-Frequency vote results. No financial guidance, outlook, or specific risk factors were disclosed in this document.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast versus shares held.
- Review the definitive Proxy Statement filed on April 23, 2025, for detailed biographies of the elected directors and the specific compensation packages approved.
- Confirm the impact of the 17,427,382 broker non-votes on the quorum and the final outcome of the director elections.
- Monitor future filings for the Company's financial performance, as this 8-K contains no operational or financial data.